Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical announced that its CEO, Dr. Steven Gourlay, will present at the 2025 Bioshares Biotech Summit, discussing the company’s late-stage Alzheimer’s trial and commercialization program. The presentation will cover the progress and potential of Xanamem, a promising therapy for Alzheimer’s and Depression, highlighting the company’s confidence in trial outcomes and interest from potential partners. The ongoing XanaMIA Phase 2b/3 trial and the upcoming XanaMIA-DUR extension trial are key components of Actinogen’s strategy to establish Xanamem as a significant player in the treatment of Alzheimer’s disease, with initial results expected in 2026.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential applications for Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments in these areas.
Average Trading Volume: 7,478,149
Technical Sentiment Signal: Sell
Current Market Cap: A$76.25M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.